Profile data is unavailable for this security.
About the company
Zelira Therapeutics Limited is an Australia-based biopharmaceutical company. The Company is engaged in the research, development and commercialization of clinically validated cannabinoid-based medicines. It owns a portfolio of products and a pipeline of candidates undergoing clinical development positioned to enter global markets. It is focused on developing and clinically validating branded cannabinoid-based medicines in its prescription (Rx) business for the treatment of a variety of medical conditions, including insomnia, autism and chronic non-cancer pain, as well as offering over the counter (OTC) products. It has two medications: HOPE and ZENIVOL. ZENIVOL is a cannabinoid-based medicine for the treatment of chronic insomnia. The Company in partnership with SprinJeneCBD, introduced a full line of oral care products, including SprinJeneCBD toothpaste product, which is a hemp-derived, oral care products containing cannabinoids, blackseed oil and zinc utilizing patented technology.
- Revenue in AUD (TTM)1.62m
- Net income in AUD-36.43m
- Incorporated2003
- Employees8.00
- LocationZelira Therapeutics LtdLevel 3, 101 St Georges TerracePERTH 6000AustraliaAUS
- Phone+61 86558-0886
- Fax+61 86316-3337
- Websitehttps://zeliratx.com/home/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BPH Global Ltd | 0.00 | -2.56m | 1.39m | 31.00 | -- | -- | -- | -- | -0.0102 | -0.0126 | 0.00 | -0.0008 | 0.00 | 0.00 | -- | -- | -177.78 | -68.17 | -784.87 | -128.99 | -- | 15.29 | -- | -131.89 | 0.5587 | -4.92 | -- | -- | -99.93 | -74.08 | 19.71 | -- | 1.34 | -- |
Holista Colltech Limited | 5.95m | -4.81m | 1.39m | 3.00 | -- | -- | -- | 0.2343 | -0.0172 | -0.0172 | 0.0213 | -0.0071 | 1.35 | 2.49 | 4.70 | -- | -111.49 | -42.59 | -347.69 | -63.58 | 56.66 | 56.37 | -82.68 | -39.27 | 0.2845 | -- | -- | -- | -27.82 | -5.65 | -230.77 | -- | -37.12 | -- |
Wellfully Ltd | 1.31m | -1.34m | 1.48m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
Hexima Ltd | 193.85k | -753.18k | 1.84m | -- | -- | 0.7221 | -- | 9.48 | -0.0045 | -0.0045 | 0.0012 | 0.0152 | 0.0558 | -- | 0.2705 | -- | -21.67 | -72.85 | -26.54 | -193.37 | -- | -- | -388.54 | -213.09 | -- | -- | 0.00 | -- | 271.52 | -19.43 | 80.85 | -- | -- | -- |
Zelira Therapeutics Ltd | 1.62m | -36.43m | 3.97m | 8.00 | -- | -- | -- | 2.45 | -3.23 | -3.23 | 0.148 | -0.2063 | 0.0848 | 0.185 | 3.55 | -- | -193.14 | -27.71 | -243.04 | -28.81 | 82.28 | -- | -2,278.17 | -508.48 | 0.1488 | -22.80 | -- | -- | -80.95 | -0.3635 | 53.35 | -- | -- | -- |
Vectus Biosystems Ltd | 86.39k | -2.49m | 4.04m | -- | -- | 1.71 | -- | 46.81 | -0.0467 | -0.0467 | 0.0016 | 0.0445 | 0.0191 | -- | -- | -- | -54.95 | -96.22 | -68.14 | -691.17 | -- | -- | -2,880.80 | -27,693.78 | -- | -439.76 | 0.00 | -- | 69,287.50 | 97.87 | 13.64 | -- | -- | -- |
Invex Therapeutics Ltd | 837.95k | -6.01m | 4.89m | -- | -- | 0.9224 | -- | 5.83 | -0.08 | -0.08 | 0.0112 | 0.0705 | 0.0521 | -- | 2.79 | -- | -37.38 | -- | -40.06 | -- | -- | -- | -717.76 | -- | -- | -- | 0.00 | -- | 379.22 | -- | -96.04 | -- | -- | -- |
Neuroscientific Biopharmaceuticals Ltd | 3.94m | 761.17k | 5.49m | -- | 7.04 | 1.44 | 6.61 | 1.40 | 0.0054 | 0.0054 | 0.0273 | 0.0264 | 1.02 | -- | 76.13 | -- | 19.64 | -55.72 | 23.29 | -60.89 | -- | -- | 19.34 | -301.54 | -- | 54.64 | 0.00 | -- | 7,292.97 | 179.97 | 89.76 | -- | -- | -- |
Island Pharmaceuticals Ltd | 10.28k | -2.37m | 9.13m | -- | -- | 10.32 | -- | 887.86 | -0.026 | -0.026 | 0.0001 | 0.007 | 0.0038 | -- | 0.0318 | -- | -88.77 | -- | -134.02 | -- | -- | -- | -23,100.68 | -- | -- | -- | 0.4433 | -- | -- | -- | -8.58 | -- | -- | -- |
Avecho Biotechnology Ltd | 473.55k | -3.44m | 9.51m | 29.00 | -- | 1.49 | -- | 20.08 | -0.0016 | -0.0016 | 0.0002 | 0.002 | 0.0888 | 2.07 | 0.5132 | -- | -64.45 | -47.08 | -75.73 | -55.25 | -9.25 | 78.67 | -725.70 | -156.43 | 8.19 | -- | 0.0267 | -- | -58.07 | -19.42 | -46.71 | -- | -- | -- |
Bioxyne Ltd | 8.65m | -14.17m | 10.23m | 16.00 | -- | 3.28 | -- | 1.18 | -0.0074 | -0.0074 | 0.0044 | 0.0015 | 1.83 | 6.12 | 10.50 | -- | -302.23 | -22.07 | -418.10 | -28.50 | 38.30 | 45.13 | -165.04 | -39.69 | 1.50 | -- | 0.00 | -- | 1,013.05 | 20.97 | -292.69 | -- | -19.86 | -- |
BTC Health Ltd | 16.03k | -8.26m | 12.64m | 1.00 | -- | 2.33 | 7.66 | 788.57 | -0.0305 | -0.0305 | 0.00005 | 0.0167 | 0.0017 | -- | 0.031 | -- | -89.67 | -23.15 | -91.36 | -24.64 | -- | -- | -51,522.02 | -2,498.18 | -- | -0.0787 | 0.00 | -- | -86.04 | -26.76 | -1,665.01 | -- | -- | -- |